{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:20:58Z","timestamp":1777540858816,"version":"3.51.4"},"reference-count":100,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2017]]},"DOI":"10.7883\/yoken.jjid.2016.356","type":"journal-article","created":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:08:44Z","timestamp":1477865324000},"page":"1-6","source":"Crossref","is-referenced-by-count":9,"title":["Poliovirus Studies during the Endgame of the Polio Eradication Program"],"prefix":"10.7883","volume":"70","author":[{"given":"Minetaro","family":"Arita","sequence":"first","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bodian D. Histopathologic basis of clinical findings in poliomyelitis. Am J Med. 1949;6:563-78.","DOI":"10.1016\/0002-9343(49)90130-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Couderc T, Christodoulou C, Kopecka H, et al. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J Gen Virol. 1989;70:2907-18.","DOI":"10.1099\/0022-1317-70-11-2907"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172:1213-29.","DOI":"10.1093\/aje\/kwq320"},{"key":"4","unstructured":"4. Landsteiner KP, E. Ubertragung der poliomyelitis acuta auf affen. Zeitschrift fur Immunitatsforschung. 1909;II:377-90."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949;109:85-7.","DOI":"10.1126\/science.109.2822.85"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bodian D. Viremia in experimental poliomyelitis. I. General aspects of infection after intravascular inoculation with strains of high and of low invasiveness. Am J Hyg. 1954;60:339-57.","DOI":"10.1093\/oxfordjournals.aje.a119726"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Salk JE, Bazeley PL, Bennett BL, et al. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am J Public Health Nations Health. 1954;44:994-1009.","DOI":"10.2105\/AJPH.44.8.994"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sabin AB. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA. 1965;194:872-6.","DOI":"10.1001\/jama.1965.03090210036010"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kitamura N, Semler BL, Rothberg PG, et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291:547-53.","DOI":"10.1038\/291547a0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Toyoda H, Kohara M, Kataoka Y, et al. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. J Mol Biol. 1984;174:561-85.","DOI":"10.1016\/0022-2836(84)90084-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci USA. 1981;78:4887-91.","DOI":"10.1073\/pnas.78.8.4887"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229:1358-65.","DOI":"10.1126\/science.2994218"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 1988;334:320-5.","DOI":"10.1038\/334320a0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56:855-65.","DOI":"10.1016\/0092-8674(89)90690-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Koike S, Horie H, Ise I, et al. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J. 1990;9:3217-24.","DOI":"10.1002\/j.1460-2075.1990.tb07520.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ren RB, Costantini F, Gorgacz EJ, et al. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 1990;63:353-62.","DOI":"10.1016\/0092-8674(90)90168-E"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Koike S, Taya C, Kurata T, et al. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA. 1991;88:951-5.","DOI":"10.1073\/pnas.88.3.951"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Evans DM, Dunn G, Minor PD, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985;314:548-50.","DOI":"10.1038\/314548a0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kawamura N, Kohara M, Abe S, et al. Determinants in the 5&rsquo; noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989;63:1302-9.","DOI":"10.1128\/JVI.63.3.1302-1309.1989"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fox MP, Otto MJ, McKinlay MA. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother. 1986;30:110-6.","DOI":"10.1128\/AAC.30.1.110"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Wikel JH, Paget CJ, DeLong DC, et al. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J Med Chem. 1980;23:368-72.","DOI":"10.1021\/jm00178a004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Molla A, Paul AV, Wimmer E. Cell-free, de novo synthesis of poliovirus. Science. 1991;254:1647-51.","DOI":"10.1126\/science.1661029"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Goodfellow I, Chaudhry Y, Richardson A, et al. Identification of a <i>cis<\/i>-acting replication element within the poliovirus coding region. J Virol. 2000;74:4590-600.","DOI":"10.1128\/JVI.74.10.4590-4600.2000"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Paul AV, Rieder E, Kim DW, et al. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J Virol. 2000;74:10359-70.","DOI":"10.1128\/JVI.74.22.10359-10370.2000"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356-9.","DOI":"10.1126\/science.1068284"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hsu NY, Ilnytska O, Belov G, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141:799-811.","DOI":"10.1016\/j.cell.2010.03.050"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Arita M, Kojima H, Nagano T, et al. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011;85:2364-72.","DOI":"10.1128\/JVI.02249-10"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Delang L, Paeshuyse J, Neyts J. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem Pharmacol. 2012;84:1400-8.","DOI":"10.1016\/j.bcp.2012.07.034"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Arita M, Kojima H, Nagano T, et al. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol. 2013;87:4252-60.","DOI":"10.1128\/JVI.03546-12"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Strating JR, van der Linden L, Albulescu L, et al. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep. 2015;10:600-15.","DOI":"10.1016\/j.celrep.2014.12.054"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Brown B, Oberste MS, Maher K, et al. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J Virol. 2003;77:8973-84.","DOI":"10.1128\/JVI.77.16.8973-8984.2003"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kilpatrick DR, Yang CF, Ching K, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol. 2009;47:1939-41.","DOI":"10.1128\/JCM.00702-09"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Arita M, Kilpatrick DR, Nakamura T, et al. Development of an efficient entire-capsid-coding-region amplification method for direct detection of poliovirus from stool extracts. J Clin Microbiol. 2015;53:73-8.","DOI":"10.1128\/JCM.02384-14"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chumakov KM, Powers LB, Noonan KE, et al. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA. 1991;88:199-203.","DOI":"10.1073\/pnas.88.1.199"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yoshida H, Horie H, Matsuura K, et al. Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan. Lancet. 2000;356:1461-3.","DOI":"10.1016\/S0140-6736(00)02868-3"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Koike S, Taya C, Aoki J, et al. Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene--influence of the transgene expression on pathogenesis. Arch Virol. 1994;139:351-63.","DOI":"10.1007\/BF01310797"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Buontempo PJ, Cox S, Wright-Minogue J, et al. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother. 1997;41:1220-5.","DOI":"10.1128\/AAC.41.6.1220"},{"key":"38","unstructured":"38. WHO. Available at &lt;http:\/\/www.polioeradication.org\/Resourcelibrary\/Strategyandwork.Annualreports.aspx&gt;. Accessed April 9, 2016."},{"key":"39","unstructured":"39. United Nations Children&rsquo;s Fund (UNICEF). Available at &lt;http:\/\/www.unicef.org\/supply\/index_57476.html&gt;. Accessed April 9, 2016."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Hovi T, Cantell K, Huovilainen A, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet. 1986;1:1427-32.","DOI":"10.1016\/S0140-6736(86)91566-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Yakovenko ML, Gmyl AP, Ivanova OE, et al. The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt. Euro Surveill. 2014;19(7): pii: 20706.","DOI":"10.2807\/1560-7917.ES2014.19.7.20706"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Tulchinsky TH, Ramlawi A, Abdeen Z, et al. Polio lessons 2013: Israel, the West Bank, and Gaza. Lancet. 2013;382:1611-2.","DOI":"10.1016\/S0140-6736(13)62331-4"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Yaari R, Kaliner E, Grotto I, et al. Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel. BMC Med. 2016;14:95.","DOI":"10.1186\/s12916-016-0637-z"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Jorba J, Diop OM, Iber J, et al. Update on Vaccine-Derived Polioviruses-Worldwide, January 2015-May 2016. MMWR Morb Mortal Wkly Rep. 2016;65:763-9.","DOI":"10.15585\/mmwr.mm6530a3"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34:1975-85.","DOI":"10.1016\/j.vaccine.2014.11.015"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Arita M, Iwai M, Wakita T, et al. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum. Clin Vaccine Immunol. 2011;18:1889-94.","DOI":"10.1128\/CVI.05225-11"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Diamond DC, Jameson BA, Bonin J, et al. Antigenic variation and resistance to neutralization in poliovirus type 1. Science. 1985;229:1090-3.","DOI":"10.1126\/science.2412292"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Blondel B, Crainic R, Fichot O, et al. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J Virol. 1986;57:81-90.","DOI":"10.1128\/JVI.57.1.81-90.1986"},{"key":"49","unstructured":"49. WHO. Available at &lt;http:\/\/www.polioeradication.org\/Portals\/0\/Document\/Resources\/PostEradication\/GAPIII_2014.pdf&gt;. Accessed April 9, 2016."},{"key":"50","unstructured":"50. WHO. Available at &lt;http:\/\/www.polioeradication.org\/Research\/Grantsandcollaboration.aspx&gt;. Accessed April 9, 2016."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Asghar H, Diop OM, Weldegebriel G, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J Infect Dis. 2014;210 Suppl 1:S294-303.","DOI":"10.1093\/infdis\/jiu384"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416-24.","DOI":"10.1056\/NEJMoa1202541"},{"key":"53","unstructured":"53. The Gates Foundation. Available at &lt;http:\/\/gcgh.grandchallenges.org\/challenge\/poliovirus-endgame-create-ways-accelerate-sustain-and-monitor-eradication-round-6&gt;. Accessed April 9, 2016."},{"key":"54","unstructured":"54. The Gates Foundation. Available at &lt;http:\/\/www.gatesfoundation.org\/What-We-Do\/Global-Development\/Reinvent-the-Toilet-Challenge-AbouttheReinventtheToiletChallenge&gt;. Accessed April 9, 2016."},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Zhang Y, Yan D, Zhu S, et al. An insight into recombination with enterovirus species C and nucleotide G-480 reversion from the viewpoint of neurovirulence of vaccine-derived polioviruses. Sci Rep. 2015;5:17291.","DOI":"10.1038\/srep17291"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Van der Sanden SM, Wu W, Dybdahl-Sissoko N, et al. Engineering enhanced vaccine cell lines to eradicate vaccine-preventable diseases: the polio end game. J Virol. 2015;90:1694-704.","DOI":"10.1128\/JVI.01464-15"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Sutter RW, Bahl S, Deshpande JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet. 2015;386:2413-21.","DOI":"10.1016\/S0140-6736(15)00237-8"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Sanders BP, de Los Rios Oakes I, van Hoek V, et al. Cold-adapted viral attenuation (CAVA): highly temperature sensitive polioviruses as novel vaccine strains for a next generation inactivated poliovirus vaccine. PLoS Pathog. 2016;12:e1005483.","DOI":"10.1371\/journal.ppat.1005483"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Knowlson S, Burlison J, Giles E, et al. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 2015;11:e1005316.","DOI":"10.1371\/journal.ppat.1005316"},{"key":"60","unstructured":"60. WHO. Available at &lt;http:\/\/apps.who.int\/iris\/bitstream\/10665\/68762\/1\/WHO_IVB_04.10.pdf&gt;. Accessed April 9, 2016."},{"key":"61","unstructured":"61. WHO. Available at &lt;http:\/\/apps.who.int\/iris\/bitstream\/10665\/67854\/1\/WHO_V-B_03.03_eng.pdf&gt;. Accessed April 9, 2016."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Arita M, Ling H, Yan D, et al. Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for a highly sensitive detection of enterovirus in the stool samples of acute flaccid paralysis cases. BMC Infect Dis. 2009;9:208.","DOI":"10.1186\/1471-2334-9-208"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Arita M. Development of poliovirus extraction method from stool extracts by using magnetic nanoparticles sensitized with soluble poliovirus receptor. J Clin Microbiol. 2013;51:2717-20.","DOI":"10.1128\/JCM.00499-13"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Sharma DK, Nalavade UP, Varose SY, et al. Vaccine-derived polioviruses not detected by global surveillance screening assay. Emerg Infect Dis. 2015;21:1880-1.","DOI":"10.3201\/eid2110.150702"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Arita M, Nagata N, Sata T, et al. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J Gen Virol. 2006;87:3317-27.","DOI":"10.1099\/vir.0.82172-0"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res. 2008;79:179-87.","DOI":"10.1016\/j.antiviral.2008.04.002"},{"key":"67","unstructured":"67. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington DC: The National Academies Press; 2006."},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Kouiavskaia DV, Dragunsky EM, Liu HM, et al. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Antivir Ther. 2011;16:999-1004.","DOI":"10.3851\/IMP1838"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Liu HM, Roberts JA, Moore D, et al. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob Agents Chemother. 2012;56:5568-74.","DOI":"10.1128\/AAC.00539-12"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Torres-Torres S, Myers AL, Klatte JM, et al. First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis. Pediatr Infect Dis J. 2015;34:52-4.","DOI":"10.1097\/INF.0000000000000497"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Molla A, Hellen CU, Wimmer E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J Virol. 1993;67:4688-95.","DOI":"10.1128\/JVI.67.8.4688-4695.1993"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Caliguiri LA, Tamm I. Action of guanidine on the replication of poliovirus RNA. Virology. 1968;35:408-17.","DOI":"10.1016\/0042-6822(68)90219-5"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Eggers HJ, Tamm I. Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole. J Exp Med. 1961;113:657-82.","DOI":"10.1084\/jem.113.4.657"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Shimizu H, Agoh M, Agoh Y, et al. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol. 2000;74:4146-54.","DOI":"10.1128\/JVI.74.9.4146-4154.2000"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. De Palma AM, Heggermont W, Lanke K, et al. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol. 2008;82:4720-30.","DOI":"10.1128\/JVI.01338-07"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Patick AK, Binford SL, Brothers MA, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43:2444-50.","DOI":"10.1128\/AAC.43.10.2444"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Dragovich PS, Prins TJ, Zhou R, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem. 2003;46:4572-85.","DOI":"10.1021\/jm030166l"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Rhoden E, Liu HM, Wang-Chern SW, et al. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res. 2013;98:186-91.","DOI":"10.1016\/j.antiviral.2013.03.003"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6:1375-9.","DOI":"10.1038\/82191"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA. 2003;100:7289-94.","DOI":"10.1073\/pnas.1232294100"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Crotty S, Saleh MC, Gitlin L, et al. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J Virol. 2004;78:3378-86.","DOI":"10.1128\/JVI.78.7.3378-3386.2004"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;69:4189-97.","DOI":"10.1128\/JVI.69.7.4189-4197.1995"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Belov GA, Kovtunovych G, Jackson CL, et al. Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1. Cell Microbiol. 2010;12:1463-79.","DOI":"10.1111\/j.1462-5822.2010.01482.x"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Arita M. Mechanism of poliovirus resistance to host phosphatidylinositol-4 kinase III &beta; inhibitor. ACS Infect Dis. 2016;2:140-8.","DOI":"10.1021\/acsinfecdis.5b00122"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Ishitsuka H, Ohsawa C, Ohiwa T, et al. Antipicornavirus flavone Ro 09-0179. Antimicrob Agents Chemother. 1982;22:611-6.","DOI":"10.1128\/AAC.22.4.611"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Galabov AS, Nikolaeva L, Philipov S. Aporphinoid alkaloid glaucinone: a selective inhibitor of poliovirus replication. Antiviral Res. 1995;26:A347.","DOI":"10.1016\/0166-3542(95)94930-Z"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518-30.","DOI":"10.1099\/vir.0.2008\/002915-0"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009;90:1869-79.","DOI":"10.1099\/vir.0.012096-0"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. De Palma AM, Thibaut HJ, van der Linden L, et al. Mutations in the non-structural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009;53:1850-7.","DOI":"10.1128\/AAC.00934-08"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. MacLeod AM, Mitchell DR, Palmer NJ, et al. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med Chem Lett. 2013;4:585-9.","DOI":"10.1021\/ml400095m"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Arita M, Philipov S, Galabov AS. Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachypodol (Ro 09-0179) for their anti-poliovirus activities, and is located at upstream of the target step of brefeldin A. Microbiol Immunol. 2015;59:338-47.","DOI":"10.1111\/1348-0421.12261"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Lamarche MJ, Borawski J, Bose A, et al. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob Agents Chemother. 2012;56:5149-56.","DOI":"10.1128\/AAC.00946-12"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Spickler C, Lippens J, Laberge MK, et al. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob Agents Chemother. 2013;57:3358-68.","DOI":"10.1128\/AAC.00303-13"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Puligedda RD, Kouiavskaia D, Adekar SP, et al. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains. Antiviral Res. 2014;108:36-43.","DOI":"10.1016\/j.antiviral.2014.05.005"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Stoyanova A, Nikolova I, Galabov AS. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on coxsackievirus B1 neuroinfection in mice. Antiviral Res. 2015;121:138-44.","DOI":"10.1016\/j.antiviral.2015.07.004"},{"key":"96","unstructured":"96. WHO. Available at &lt;http:\/\/www.polioeradication.org\/Posteradication\/Certification.aspx&gt;. Accessed April 9, 2016."},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science. 2002;297:1016-8.","DOI":"10.1126\/science.1072266"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Arita M, Zhu SL, Yoshida H, et al. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J Virol. 2005;79:12650-7.","DOI":"10.1128\/JVI.79.20.12650-12657.2005"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Jiang P, Faase JA, Toyoda H, et al. Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. Proc Natl Acad Sci USA. 2007;104:9457-62.","DOI":"10.1073\/pnas.0700451104"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Jegouic S, Joffret ML, Blanchard C, et al. Recombination between polioviruses and co-circulating coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog. 2009;5:e1000412.","DOI":"10.1371\/journal.ppat.1000412"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/70\/1\/70_JJID.2016.356\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T01:33:17Z","timestamp":1601170397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/70\/1\/70_JJID.2016.356\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2016.356","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}